News
GKOS
163.81
+1.48%
2.39
Weekly Report: what happened at GKOS last week (0914-0918)?
Weekly Report · 1h ago
10 large and mega-cap U.S. healthcare stocks with the strongest momentum grades
Seeking Alpha · 3d ago
Is Glaukos (GKOS) A Bargain After Its Big Run Higher?
Simply Wall St · 6d ago
Weekly Report: what happened at GKOS last week (0907-0911)?
Weekly Report · 09/14 10:00
Weekly Report: what happened at GKOS last week (0831-0904)?
Weekly Report · 09/07 09:55
Noteworthy ETF Outflows: SPSM, CORT, GKOS, PAYC
NASDAQ · 09/04 14:51
Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbbVie (ABBV)
TipRanks · 09/04 13:40
Chief Development Officer Of Glaukos Sold 28% Of Their Shares
Simply Wall St · 09/03 10:04
Small-cap bears were back. Was IWM the warning sign?
Seeking Alpha · 09/02 15:29
Ten healthcare stocks leading in year-over-year CapEx growth
Seeking Alpha · 09/02 12:02
Top Glaukos Executive Makes Bold Insider Move in High-Value Stock Sale
TipRanks · 09/02 02:06
Glaukos (GKOS) On The iDose TR Narrative And Why Valuation Still Draws Attention
Simply Wall St · 08/31 10:18
Weekly Report: what happened at GKOS last week (0824-0828)?
Weekly Report · 08/31 10:01
Noteworthy ETF Inflows: IWO, GKOS, EAT, FROG
NASDAQ · 08/24 15:06
Weekly Report: what happened at GKOS last week (0817-0821)?
Weekly Report · 08/24 10:01
Glaukos (GKOS), Why Is The Story Getting Harder To Ignore?
Simply Wall St · 08/24 04:45
Glaukos (GKOS) Stock Looks Pricey On High Growth Expectations
Simply Wall St · 08/20 16:26
Okta To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga · 08/20 12:19
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 08/20 11:40
Glaukos Price Target Raised to $202.00/Share From $193.00 by BTIG
Dow Jones · 08/20 10:25
More
Webull provides a variety of real-time GKOS stock news. You can receive the latest news about Glaukos Corp through multiple platforms. This information may help you make smarter investment decisions.
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.